INO-4800

Short description: COVID-19 vaccine candidate

INO-4800Vaccine description

Target disease| SARS-CoV-2
Type| DNA vaccination
Clinical data
Other names| Inovio COVID-19 Vaccine
Routes of
administration| Intramuscular
Identifiers
DrugBank|

* DB15693

INO-4800 is a COVID-19 vaccine candidate developed by Inovio Pharmaceuticals.

## Contents

* 1 Development
* 1.1 Clinical research
* 2 References
* 3 External links

## Development

In February 2020 after receiving details of the genetic sequence of the coronavirus, Inovio announced that it had produced a preclinical DNA-based vaccine as a potential therapy for COVID-19.[1][2] Inovio is in competition to develop a coronavirus vaccine with numerous other companies, which were conducting preclinical or early-stage human research on more than 170 vaccine candidates, as of late June.[3] In April 2020, Inovio began a Phase I trial of the COVID-19 vaccine candidate, INO-4800.[4]

### Clinical research

Inovio is collaborating with Beijing Advaccine Biotechnology Co., a Chinese biotech firm,[2] in order to speed its acceptance by regulatory authorities in China , with plans to begin human clinical trials of a candidate vaccine in China during the first half of 2020.[5][6] Inovio has partnerships with manufacturers to scale up production of a vaccine if preliminary efficacy trials are successful.[2] In April 2020, the company began human Phase I safety studies of its lead vaccine (INO-4800) in the United States, and a Phase I-II trial in South Korea, to test for immunization against the COVID-19 virus.[5][7]

In early June, Inovio partnered with the International Vaccine Institute and Seoul National University, South Korea , to advance human research on INO-4800 in a Phase I-II safety and efficacy trial to be conducted on 120 participants at Seoul National University Hospital beginning in June.[8] The trial is funded by the Coalition for Epidemic Preparedness Innovations and supported by the Korea Centers for Disease Control and Prevention and the Korea National Institute of Health.[8]

## References

1. ↑ "Inovio shares rally after biotech says human trials of coronavirus vaccine will start in April". MarketWatch. 8 March 2020. https://www.marketwatch.com/story/inovio-shares-rally-after-biotech-says-human-trials-of-coronavirus-vaccine-will-start-in-april-2020-03-03.
2. ↑ 2.0 2.1 2.2 "Is a vaccine for the coronavirus coming? Inovio says it has designed one in San Diego". Los Angeles Times. https://www.latimes.com/business/story/2020-02-15/coronavirus-vaccine-design-inovio-san-diego.
3. ↑ "COVID-19 vaccine tracker (Select vaccine tab)". Milken Institute. 22 June 2020. https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viwDBH7b6FjmIBX5x?blocks=bipZFzhJ7wHPv7x9z.
4. ↑ Clinical trial number NCT04336410 for "Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers" at ClinicalTrials.gov
5. ↑ 5.0 5.1 "The COVID-19 vaccine development landscape". Nature Reviews. Drug Discovery 19 (5): 305–306. May 2020. doi:10.1038/d41573-020-00073-5. PMID 32273591. https://www.nature.com/articles/d41573-020-00073-5.
6. ↑ "Coronavirus: Scientists race to develop a vaccine". BBC News - Health. 30 January 2020. https://www.bbc.com/news/health-51299735.
7. ↑ "IVI, INOVIO, and KNIH to partner with CEPI in a Phase I/II clinical trial of INOVIO's COVID-19 DNA vaccine in South Korea". International Vaccine Institute. 2020-04-16. https://www.ivi.int/ivi-inovio-and-knih-to-partner-with-cepi-in-a-phase-i-ii-clinical-trial-of-inovios-covid-19-dna-vaccine-in-south-korea/.
8. ↑ 8.0 8.1 "IVI and SNU partner to trial Inovio Covid-19 vaccine in Korea". Clinical Trials Arena. 2020-06-05. https://www.clinicaltrialsarena.com/news/ivi-snu-inovio-vaccine-trial/.

## External links

0.00

(0 votes)

|

Retrieved from "https://handwiki.org/wiki/index.php?title=Medicine:INO-4800&oldid=755685"